{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:54:09Z","timestamp":1762073649003,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Iuliu Ha\u021bieganu University of Medicine and Pharmacy","award":["1680\/22\/19.01.2018"],"award-info":[{"award-number":["1680\/22\/19.01.2018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>(1) Background: Chronic myeloid leukemia (CML) is a blood dyscrasia that accounts for about 20% of all leukemia cases. Tyrosine kinase inhibitors (TKIs) are used as first line treatment of CML. The 2019 SARS-CoV-2 outbreak raised new concerns for CML patients, such as whether CML increases the risk of contracting COVID-19, whether TKIs increase that risk, whether these drugs are safe to use during the infection, and whether any other hematologic parameters influence infection outcomes. (2) Methods: In our study we addressed these intriguing questions by using a retrospective analysis of 51 CML patients treated at the Ion Chiricuta Cancer Center, Cluj-Napoca, Romania. Furthermore, we investigated the effects of currently approved COVID-19 vaccines in our CML patients treated with tyrosine kinase inhibitors. (3) Results: Our results have shown that hemoglobin level upon diagnosis of CML has been the only hematologic parameter correlated to the risk of contracting COVID-19 in our CML patients. (4) Conclusions: TKI treatment did not negatively influence COVID-19 risk or the response to the vaccine in our patients. The safety profile of the currently approved COVID-19 vaccines was similar to that of the general population.<\/jats:p>","DOI":"10.3390\/jpm12111886","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T19:17:34Z","timestamp":1668107854000},"page":"1886","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["COVID-19 Impact on Chronic Myeloid Leukemia Patients"],"prefix":"10.3390","volume":"12","author":[{"given":"Dana Raluca","family":"Arbore","sequence":"first","affiliation":[{"name":"Department of Hematology, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona Maria","family":"Galdean","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"Dima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Rus","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6252-6281","authenticated-orcid":false,"given":"David","family":"Kegyes","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"MEDFUTURE Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca Geanina","family":"Ababei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Dragancea","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu Andrei","family":"Tomai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-8643","authenticated-orcid":false,"given":"Adrian Pavel","family":"Trifa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-1519","authenticated-orcid":false,"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400012 Cluj-Napoca, Romania"},{"name":"MEDFUTURE Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4909012","DOI":"10.1155\/2021\/4909012","article-title":"Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations","volume":"2021","author":"Asif","year":"2021","journal-title":"Anal. Cell. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fonc.2019.00863","article-title":"Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology","volume":"23","author":"Moisoiu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v13020202","article-title":"COVID-19: A Review on the Novel Coronavirus Disease","volume":"13","author":"Sharma","year":"2021","journal-title":"Viruses"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Claudiani, S., Rosadas, C., McClure, M., Khan, M., Tedder, R.S., Innes, A.J., Milojkovic, D., and Apperley, J. (2022, August 14). Prevalence of SARS-Cov-2 Infection in Patients with Chronic Myeloid Leukemia. Available online: http:\/\/doi.org\/10.1182\/blood-2020-142454.","DOI":"10.1182\/blood-2020-142454"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11912-021-01111-0","article-title":"The Care of the Leukemic Patients in Times of SARS-CoV-2","volume":"23","author":"Karki","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-140161","article-title":"COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study","volume":"136","author":"Rea","year":"2020","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ccell.2021.07.001","article-title":"Immune responses to COVID-19 vaccines in patients with cancers: Positive results and a note of caution","volume":"39","author":"Griffiths","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1159\/000508378","article-title":"Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome","volume":"13","author":"Abdalhadi","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-020-0853-6","article-title":"COVID-19 in persons with chronic myeloid leukaemia","volume":"34","author":"Li","year":"2020","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3389\/fphar.2019.01232","article-title":"Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection","volume":"10","author":"Climent","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2021022","DOI":"10.4084\/mjhid.2021.022","article-title":"Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption","volume":"13","author":"Demeter","year":"2021","journal-title":"Mediterr J. Hematol. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3109\/10428194.2014.940582","article-title":"BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice","volume":"56","author":"Tomuleasa","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3389\/fonc.2019.00872","article-title":"Persistent Basophilia May Suggest an \u201cAccelerated Phase\u201d in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia","volume":"9","author":"Dobrowolski","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"994101","DOI":"10.3389\/fonc.2022.994101","article-title":"Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase","volume":"12","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Graf, I., Herndlhofer, S., Kundi, M., Greiner, G., Sperr, M., Hadzijusufovic, E., Valent, P., and Sperr, W. (2022). Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population. Eur. J. Haematol., 1\u201310.","DOI":"10.1111\/ejh.13875"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e29660","DOI":"10.1097\/MD.0000000000029660","article-title":"Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review","volume":"101","author":"Asif","year":"2022","journal-title":"Medicine"},{"key":"ref_21","first-page":"e23863","article-title":"SARS-CoV-2 Omicron Variant in Patients with Chronic Myeloid Leukemia: A Retrospective Study","volume":"14","author":"Ali","year":"2022","journal-title":"Cureus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11912-021-01169-w","article-title":"What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?","volume":"24","author":"Delgado","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1080\/10428194.2022.2027403","article-title":"Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: Results from a seroprevalence study","volume":"63","author":"Claudiani","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","first-page":"2260","article-title":"Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy","volume":"34","author":"Breccia","year":"2020","journal-title":"Campus CML Surv. Leuk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/10105395221112836","article-title":"Antibody Response Post-COVID-19 Vaccination in Patients with Chronic Myeloid Leukemia with Comparison Between Comirnaty and CoronaVac Vaccine","volume":"34","author":"Kuan","year":"2022","journal-title":"Asia Pac. J. Public Health"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.18001","article-title":"Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors","volume":"197","author":"Claudiani","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.17568","article-title":"Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia","volume":"194","author":"Harrington","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"Hehlmann. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_29","unstructured":"Team, R.C. (2022, September 06). R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing. Available online: https:\/\/www.r-project.org."},{"key":"ref_30","first-page":"68","article-title":"Imatinib a Tyrosine Kinase Inhibitor: A potential treatment for SARS- COV-2","volume":"56","author":"Assad","year":"2020","journal-title":"Alex. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection","volume":"58","author":"Coleman","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4049\/jimmunol.182.Supp.33.8","article-title":"Dasatinib potential for anti-inflammatory efficacy while avoiding suppression of T cell activation in preclinical models","volume":"182","author":"Schieven","year":"2009","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/BJ20141165","article-title":"The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases","volume":"465","author":"Ozanne","year":"2015","journal-title":"Biochem. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_36","first-page":"198","article-title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","volume":"190","author":"Innes","year":"2020","journal-title":"BJHaem"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Gonz\u00e1lez-Gay, Tsutomu Takeuchi. Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101489","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_39","first-page":"1","article-title":"Clinical significance of early IgA antiSARSCoV2 antibody detection in patients from a Romanian referral COVID-19 hospital","volume":"22","author":"Anita","year":"2022","journal-title":"Exp. Ther. Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/11\/1886\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:13:52Z","timestamp":1760145232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/11\/1886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jpm12111886"],"URL":"https:\/\/doi.org\/10.3390\/jpm12111886","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}